Betapace AF

• Anti-Ulcer Agents
• ATC:A02BX02

• Betapace
• Betapace AF
• Sorine
• Sotalol HCL

• No information avaliable

C₁₁H₈₇Al₉O₅₅S₈

http://www.rxlist.com/cgi/generic/sucral.htm

Betapace_AF MSDS

No information avaliable

1599.14 g/mol

No information avaliable

Insoluble in cold water

Solid

No information avaliable

Suspension; Tablet for oral administration (1g)

For the short-term treatment (up to 8 weeks) of active duodenal ulcer. Also used as maintenance therapy for duodenal ulcer patients at reduced dosage (1 gram twice a day) after healing of acute ulcers.

Sucralfate is a prescription medication used to treat peptic ulcers. The current clinical uses of sucralfate are limited. It is effective for the healing of duodenal ulcers, but it is not frequently used for this since more effective drugs (e.g. proton pump inhibitors) have been developed. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. Chemically, sucralfate is a complex of the disaccharide sugar, sucrose, combined with sulfate and aluminum. In acidic solutions (e.g. gastric acid) it forms a thick paste that has a strong negative charge.

Minimally absorbed from the gastrointestinal tract (up to 5% of the disaccharide component and less than 0.02% of aluminum).

Acute oral toxicity (LD₅₀) in mice is >8000 mg/kg. There is limited experience in humans with overdosage of sucralfate. Sucralfate is only minimally absorbed from the gastrointestinal tract and thus risks associated with acute overdosage should be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic.

Humans and other mammals